Medicilon(SH:688202) Zheng Quan Zhi Xing·2025-08-29 17:01Core Viewpoint - Shanghai Medicy Bio-Pharmaceutical Co., Ltd. has announced a stock incentive plan involving the issuance of restricted stocks to attract and retain talent, enhance team cohesion, and align the interests of shareholders, the company, and core team members [1][2][3]. Group 1: Stock Incentive Plan Overview - The incentive plan will grant a total of 1 million restricted stocks, with 800,000 stocks (80%) for initial grants and 200,000 stocks (20%) reserved for future allocation [3][4]. - The stocks will be sourced from the company's repurchased A-shares in the secondary market, with a repurchase average price of 31.21 RMB per share [3][4]. - The plan aims to improve corporate governance and establish a long-term incentive mechanism [1][2]. Group 2: Eligibility and Distribution - The incentive plan targets 385 core employees, excluding independent directors and supervisors, with the aim of including foreign employees due to competitive talent demands [5][6]. - The distribution of restricted stocks will be based on performance evaluations, with a maximum of 1% of the total share capital allocated to any individual [4][6]. Group 3: Vesting Conditions and Performance Metrics - The vesting period for the restricted stocks is set for a maximum of 48 months, with specific performance targets for 2025 and 2026, including revenue growth of at least 10% and 20% respectively [14][16]. - The performance evaluation will consider both company-level metrics (revenue and net profit) and individual performance ratings [16][17]. Group 4: Accounting and Financial Impact - The estimated total cost for the incentive plan is projected at 22.57 million RMB, which will be recognized as an expense over the vesting period [24][26]. - The plan is expected to positively influence the company's long-term performance by motivating employees and improving operational efficiency [26].